vs
Antero Midstream Corp（AM）とAmphastar Pharmaceuticals, Inc.（AMPH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Antero Midstream Corpの直近四半期売上が大きい（$291.1M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.6倍）。Antero Midstream Corpの純利益率が高く（41.5% vs 13.3%、差は28.1%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -7.3%）。Antero Midstream Corpの直近四半期フリーキャッシュフローが多い（$186.9M vs $24.6M）。過去8四半期でAntero Midstream Corpの売上複合成長率が高い（3.9% vs 3.2%）
Antero Midstream Corpは米国のエネルギー企業で、デラウェア州に法人登録され、本社をコロラド州デンバーに置く。同社の石油・天然ガス埋蔵量は全てアパラチア盆地にあり、水圧破砕技術を用いて採掘を行っている。
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
AM vs AMPH — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $291.1M | $183.1M |
| 純利益 | $120.7M | $24.4M |
| 粗利率 | — | 46.8% |
| 営業利益率 | 60.9% | 19.4% |
| 純利益率 | 41.5% | 13.3% |
| 売上前年比 | -7.3% | -1.8% |
| 純利益前年比 | 2.1% | -35.7% |
| EPS（希薄化後） | $0.25 | $0.51 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $291.1M | — | ||
| Q4 25 | $297.0M | $183.1M | ||
| Q3 25 | $294.8M | $191.8M | ||
| Q2 25 | $305.5M | $174.4M | ||
| Q1 25 | $291.1M | $170.5M | ||
| Q4 24 | $287.5M | $186.5M | ||
| Q3 24 | $269.9M | $191.2M | ||
| Q2 24 | $269.8M | $182.4M |
| Q1 26 | $120.7M | — | ||
| Q4 25 | $51.9M | $24.4M | ||
| Q3 25 | $116.0M | $17.4M | ||
| Q2 25 | $124.5M | $31.0M | ||
| Q1 25 | $120.7M | $25.3M | ||
| Q4 24 | $111.2M | $38.0M | ||
| Q3 24 | $99.7M | $40.4M | ||
| Q2 24 | $86.0M | $37.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 46.8% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | 46.5% | ||
| Q3 24 | — | 53.3% | ||
| Q2 24 | — | 52.2% |
| Q1 26 | 60.9% | — | ||
| Q4 25 | 33.8% | 19.4% | ||
| Q3 25 | 61.2% | 13.2% | ||
| Q2 25 | 61.0% | 24.2% | ||
| Q1 25 | 60.9% | 21.9% | ||
| Q4 24 | 61.8% | 24.2% | ||
| Q3 24 | 60.2% | 29.8% | ||
| Q2 24 | 56.6% | 30.3% |
| Q1 26 | 41.5% | — | ||
| Q4 25 | 17.5% | 13.3% | ||
| Q3 25 | 39.3% | 9.0% | ||
| Q2 25 | 40.8% | 17.8% | ||
| Q1 25 | 41.5% | 14.8% | ||
| Q4 24 | 38.7% | 20.4% | ||
| Q3 24 | 37.0% | 21.1% | ||
| Q2 24 | 31.9% | 20.8% |
| Q1 26 | $0.25 | — | ||
| Q4 25 | $0.11 | $0.51 | ||
| Q3 25 | $0.24 | $0.37 | ||
| Q2 25 | $0.26 | $0.64 | ||
| Q1 25 | $0.25 | $0.51 | ||
| Q4 24 | $0.23 | $0.74 | ||
| Q3 24 | $0.21 | $0.78 | ||
| Q2 24 | $0.18 | $0.73 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.4M | $282.8M |
| 総負債低いほど良い | $3.2B | $608.7M |
| 株主資本純資産 | $2.0B | $788.8M |
| 総資産 | $5.9B | $1.6B |
| 負債/資本比率低いほどレバレッジが低い | 1.63× | 0.77× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $180.4M | — | ||
| Q4 25 | $180.4M | $282.8M | ||
| Q3 25 | — | $276.2M | ||
| Q2 25 | — | $231.8M | ||
| Q1 25 | — | $236.9M | ||
| Q4 24 | — | $221.6M | ||
| Q3 24 | — | $250.5M | ||
| Q2 24 | — | $217.8M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $608.7M | ||
| Q3 25 | $3.0B | $608.6M | ||
| Q2 25 | $3.0B | $607.7M | ||
| Q1 25 | $3.1B | $603.9M | ||
| Q4 24 | $3.1B | $601.6M | ||
| Q3 24 | $3.2B | $596.4M | ||
| Q2 24 | $3.2B | $586.9M |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $788.8M | ||
| Q3 25 | $2.1B | $776.7M | ||
| Q2 25 | $2.1B | $757.5M | ||
| Q1 25 | $2.1B | $751.3M | ||
| Q4 24 | $2.1B | $732.3M | ||
| Q3 24 | $2.1B | $727.7M | ||
| Q2 24 | $2.1B | $713.3M |
| Q1 26 | $5.9B | — | ||
| Q4 25 | $5.9B | $1.6B | ||
| Q3 25 | $5.7B | $1.7B | ||
| Q2 25 | $5.7B | $1.6B | ||
| Q1 25 | $5.8B | $1.6B | ||
| Q4 24 | $5.8B | $1.6B | ||
| Q3 24 | $5.8B | $1.5B | ||
| Q2 24 | $5.8B | $1.5B |
| Q1 26 | 1.63× | — | ||
| Q4 25 | 1.63× | 0.77× | ||
| Q3 25 | 1.46× | 0.78× | ||
| Q2 25 | 1.45× | 0.80× | ||
| Q1 25 | 1.49× | 0.80× | ||
| Q4 24 | 1.47× | 0.82× | ||
| Q3 24 | 1.49× | 0.82× | ||
| Q2 24 | 1.50× | 0.82× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $198.9M | $32.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $186.9M | $24.6M |
| FCFマージンFCF / 売上 | 64.2% | 13.4% |
| 設備投資強度設備投資 / 売上 | 11.1% | 4.5% |
| キャッシュ転換率営業CF / 純利益 | 1.65× | 1.35× |
| 直近12ヶ月FCF直近4四半期 | — | $121.2M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $198.9M | — | ||
| Q4 25 | $255.5M | $32.9M | ||
| Q3 25 | $212.8M | $52.6M | ||
| Q2 25 | $265.2M | $35.6M | ||
| Q1 25 | $198.9M | $35.1M | ||
| Q4 24 | $232.7M | $29.0M | ||
| Q3 24 | $184.9M | $60.0M | ||
| Q2 24 | $215.8M | $69.1M |
| Q1 26 | $186.9M | — | ||
| Q4 25 | — | $24.6M | ||
| Q3 25 | — | $47.2M | ||
| Q2 25 | — | $25.0M | ||
| Q1 25 | — | $24.4M | ||
| Q4 24 | — | $16.6M | ||
| Q3 24 | $184.3M | $46.2M | ||
| Q2 24 | $147.2M | $63.1M |
| Q1 26 | 64.2% | — | ||
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 24.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 14.3% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | 68.3% | 24.1% | ||
| Q2 24 | 54.6% | 34.6% |
| Q1 26 | 11.1% | — | ||
| Q4 25 | — | 4.5% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 6.3% | ||
| Q4 24 | 0.0% | 6.7% | ||
| Q3 24 | 0.2% | 7.2% | ||
| Q2 24 | 25.4% | 3.3% |
| Q1 26 | 1.65× | — | ||
| Q4 25 | 4.92× | 1.35× | ||
| Q3 25 | 1.84× | 3.03× | ||
| Q2 25 | 2.13× | 1.15× | ||
| Q1 25 | 1.65× | 1.39× | ||
| Q4 24 | 2.09× | 0.76× | ||
| Q3 24 | 1.85× | 1.48× | ||
| Q2 24 | 2.51× | 1.82× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AM
| Gathering and compression–Antero Resources | $238.0M | 82% |
| Other | $52.3M | 18% |
| Water handling–third party | $505.0K | 0% |
| Gathering and compression–third party | $295.0K | 0% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
